EyePoint completes patient enrolment in study of NPDR therapy

Topline data from the trial are anticipated in the second quarter of next year.

June 06 2023

US-based pharmaceutical company EyePoint Pharmaceuticals has finished enrolling patients in its Phase II PAVIA clinical trial of EYP-1901 for moderate to severe non-proliferative diabetic retinopathy (NPDR).

The randomised, controlled study will evaluate EYP-1901 as a potential nine-month treatment for patients with moderate to severe NPDR.

The 12-month trial has exceeded its 60-patient target and enrolled a total of 77 patients.

Patients were randomised to receive either 2mg or 3mg of EYP-1901 while the control group was treated with a sham intravitreal injection in the physician's office.

The improvement of at least two diabetic retinopathy severity scale levels as of week 36 after the EYP-1901 injection is the trial's primary efficacy endpoint.

Secondary endpoints include the reduction in retinal ischaemia/nonperfusion and safety, as well as the occurrence of diabetic macular oedema and/or proliferative disease and vision-threatening complications.

Topline data from the trial are anticipated in the second quarter of next year.

EyePoint Pharmaceuticals CEO Nancy Lurker said: “Despite the risk for visual loss associated with this disease, over 90% of patients currently receive no course of treatment apart from observation by their eye care specialist until they develop sight-threatening complications.

“This is due to the burdensome and frequent eye injections currently required with today’s approved therapies for this disease.

“As a result, we believe EYP-1901 may address the substantial therapeutic unmet need for a long-acting treatment.”

EYP-1901 combines an erodible formulation of Durasert E with tyrosine kinase inhibitor, vorolanib.

The therapy is being developed as an investigational sustained delivery treatment for retinal diseases.

A previous Phase I clinical trial of EYP-1901 in wet AMD demonstrated a positive safety profile with stable visual acuity and OCT.

Data from the trial showed a 75% treatment burden reduction after six months and 73% at the 12-month visit following one dose of EYP-1901.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close